Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors

Nuclear Medicine and Biology

Volumn 31, Issue 4, 2004, Pages 469-476

  Mishani, Eyal ^a   Abourbeh, Galith ^a,b   Rozen, Yulia ^a   Jacobson, Orit ^a   Laky, Desideriu ^a   David, Iris Ben ^a   Levitzki, Alexander ^b   Shaul, Mazal ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

C 11 MeI; Carbon 11; EGFR TK; PET

Indexed keywords

4 (3,4 DICHLORO 6 FLUOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 DIMETHYLAMINOBUT 2 ENOIC ACID[4 (3 BROMOPHENYLAMINO)QUINAZOLIN 6 YL]AMIDE C 11; 4 DIMETHYLAMINOBUT 2 ENOIC ACID[4 (3 IODOPHENYLAMINO)QUINAZOLIN 6 YL]AMIDE C 11; 4 DIMETHYLAMINOBUT 2 ENOIC ACID[4 (3,4 DICHLORO 6 FLUOROPHENYLAMINO)QUINAZOLIN 6 YL]AMIDE C 11; 6 ACRYLAMIDO 4 (3,4 DICHLORO 6 FLUOROANILINO)QUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE; RECEPTOR BLOCKING AGENT; TRACER; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY; PROTEIN PHOSPHORYLATION; RADIOCHEMISTRY; RADIOISOTOPE DECAY; SUBSTITUTION REACTION;

CARBON RADIOISOTOPES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FEASIBILITY STUDIES; HUMANS; MOLECULAR PROBES; QUINAZOLINES; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 1842850604     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2003.12.005     Document Type: Article

References (19)

1. Ritter R., Arteaga C.L. The epidermal growth factor receptor-tyrosine kinase a promising therapeutic target in solid tumors. Semin Oncol. 30:2003;3-11.
2. Raymond E., Faivre S., Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 60:2000;15-23.
3. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 19:1995;183-232.
4. Voldborg B.R., Damstrup L., Spang-Thomsen M., Poulsen H.S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 81:1997;197-206.
5. Walsh J.C., Maclean D., Northrop J., Padgett H., Ysaguirre T. A combinatorial strategy for the design and synthesis of 18F-labeled quinoline derivatives as kinase imaging agents. J Label Compd Radiopharm. 46:2003;S48.
6. VanBrocklin H.F., Dorff P.N., Vasdev N., O'Neil J.P., Nandanan E., Gibbs A.R. Synthesis of 2′-, 3′- and 4′-[F18] fluoroanilinoquinazoline. J Label Compd Radiopharm. 46:2003;S117.
7. Ackermann U., Tochon-Dabguy H., Nice E., Nerrie M., Young K., Sachinidis J., Scott A. Synthesis, radiolabeling and biological evaluation of derivatives of the P210BCR-ABL tyrosine kinase inhibitor AG957. J Label Compd Radiopharm. 46:2003;S118.
8. Kesarios N., Tochon-Danguy H.-J., Ackermann U., Sachinidis J., Lambert J., Nerrie M., Nice E., Scott A. Synthesis and radiolabeling of a tyrosine kinase inhibitor of erbB2/neu (HER2) receptors. J Label Compd Radiopharm. 46:2003;S119.
9. Mishani E., Bonasera T.A., Rozen Y., Ortu G., Gazit A., Levitzki A. Fluorinated EGFR-TK inhibitors-based tracers for PET. J Label Compd Radiopharm. 42:1999;S27-29.
10. Mishani E., Abourbeh G., Ortu G., Rozen Y., Ben-David I., Froimovaci S., Dissoki S., Gazit A., Levitzki A. Novel EGFR irreversible tyrosine kinase inhibitor candidates for the diagnostic and therapeutic treatment of cancer. J Label Compd Radiopharm. 46:2003;S115.
11. Mishani E., Abourbeh G., Rozen Y., Laki D., Levitzki A. Carbon-11 labeling of 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]- amides, a new class of EGFR irreversible inhibitors. J Label Compd Radiopharm. 46:2003;S2.
12. Bonasera T.A., Ortu G., Rozen Y., Krais R., Freedman N.M., Chisin R., Gazit A., Levitzki A., Mishani E. Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol. 28:2001;359-374.
13. Ortu G., Ben-David I., Rozen Y., Freedman N.M.T., Chisin R., Levitzki A., Mishani E. Labeled EGFRTK irreversible inhibitor (ML03). In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int J Cancer. 101:2002;360-370.
14. Ben-David I., Rozen Y., Ortu G., Mishani E. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon [C-11]Acryloyl chloride. Appl Radiat Isot. 58:2003;209-217.
15. Tsou H.R., Mamuya N., Johnson B.D., Reich M.F., Gruber B.C., Ye F., Nilakantan R., Shen R., Discafani C., DeBlanc R., Davis R., Koehn F.E., Greenberger L.M., Wang Y.F., Wissner A. 6-Substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity. J Med Chem. 44:2001;2719-2734.
16. Morley JS, Simpson JCE. The chemistry of simple heterocyclic systems. Part I. Reactions of 6- and 7-nitro-4-hydroxyquinazoline and their derivatives. J Chem Soc 1948;360-6.
17. Mishani E., Cristel M.E., Dence C.S., McCarthy T.J., Welch M.J. Application of a novel phenylpiperazine formation reaction to the radiosynthesis of a model fluorine-18-labeled radiopharmaceutical (18FTFMPP). Nucl Med Biol. 24:1997;269-273.
18. Crouzel C., Langstrom B., Pike V.W., Coenen H.H. Recommendation for a practical production of [C-11]MeI. Int J Appl Radiat Isot. 38:1987;601-604.
19. Smaill J.B., Palmer B.D., Rewcastle G.W., Denny W.A., McNamara D.J., Dobrusin E.M., Bridges A.J., Zhou H., Hollis Showalter H.D., Winters R.T., Leopold W.R., Fry D.W., Nelson J.M., Slintal V., Elliot W.L., Roberts B.J., Vincent P.W., Patmore S.J. Tyrosine kinase inyibitors. 15. 4-(phenylamino) quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of ATP binding site of the epidermal growth factor receptor. J Med Chem. 42:1999;1803-1815.